NEGGRAM
LOE ApproachingNDAORALSUSPENSION
Approved
Apr 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEGGRAM is an oral suspension small-molecule drug approved in 1973 by Sanofi. The specific indication and mechanism of action are not documented in available data. This is a legacy product approaching loss of exclusivity.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30) suggests declining brand team resources and a shrinking market footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring on this product line. Working on NEGGRAM offers limited career trajectory given its LOE-approaching status and declining market relevance.
Brand ManagerField Sales
Worked on NEGGRAM at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.